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The United States Food and Drug Administration (FDA) required that as of January 1, 
1998, manufacturers of enriched cereal-grain products fortify their products with folic 
acid to reduce the number of pregnancies affected by a neural tube defect (NTD). Prior to 
adoption of the regulation in 1996, three economic evaluations projected the net 
economic benefits or cost savings of folic acid fortification. The expected percentage 
decline in NTDs in these three studies was between 2.6% and 10.5%. Birth defects 
surveillance data indicate that since fortification there has been a 20% to 30% decline in 
births with either spina bifida or anencephaly. We estimate that folic acid fortification is 
associated with an economic benefit of $425 million per year in the United States and 
constitutes a major public health success that has resulted from regulatory action
Abstract
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On March 5, 1996, the United States Food and Drug Administration (FDA) 
required that by January 1, 1998, manufacturers of enriched cereal-grain products fortify 
their products with 140 micrograms of folic acid per 100 grams of cereal-grain product.1 
This decision invoked the regulatory power of the federal government to ensure that 
women at risk of becoming pregnant would be provided effective access to a nutrient that 
can prevent a substantial proportion of neural tube defects (NTDs).2
Prior to the adoption of the fortification regulation in 1996, three economic 
evaluations projected that positive net economic benefits would result from fortification.3'
5 To date, no analysis has evaluated the costs and benefits realized by implementation of 
fortification. We find that the actual economic benefits substantially exceed the 
forecasted benefits.
Economic evaluation and the policy process
Economic evaluation plays an important role in translating research findings into 
practice and policy. Economic evaluations can be either ex ante, conducted prior to the 
adoption of a policy on the basis of results from pilot studies and theoretical assumptions, 
or ex post, carried out after implementation utilizing information on observed outcomes. 
Only rarely are the findings of ex ante economic analyses compared with the actual 
results of policies.
Since the Reagan administration, the Executive branch has required federal 
regulatory agencies to conduct a regulatory impact analysis (RIA) of proposed rules. 
Under Executive Order 12866 signed in 1993, “significant regulatory actions” are to be 
accompanied by an assessment of expected costs and benefits.6
Introduction
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Two major types of methods of economic evaluation are used to inform policy 
decisions affecting public health and safety. One is cost-benefit analysis (CBA), also 
commonly referred to as benefit-cost analysis. A CBA values all outcomes in monetary 
terms, including deaths and cases of disease averted. The other type of study is cost- 
effectiveness analysis (CEA). A CEA calculates the ratio of net costs (intervention costs 
minus medical and other direct costs averted from prevention) to the numbers of health 
outcomes.7 Health outcomes can be expressed in natural units (e.g., deaths averted) or in 
terms of a combined measure such as quality-adjusted life years or QALYs.
Until recently, regulatory analyses have mostly taken the form of CBAs. In 
contrast, most studies published in medical or public health journals have been CEAs. In 
September 2003, the Office of Management and the Budget directed agencies to begin 
using both CEA and CBA, where feasible, “for all major rulemakings for which the 
primary benefits are improved public health and safety.”8-9
Economic evaluations do not necessarily determine regulatory decisions. Each 
federal agency is governed by specific legislation. In particular, the Food, Drug, and 
Cosmetic Act requires FDA to base regulatory decisions on safety and efficacy.10 For 
food additives, FDA follows a safety standard of a reasonable certainty of no harm and 
does not take into account projected economic benefit..
Folic Acid and Health Outcomes
Between 1981 and 1992, several studies reported that consumption of vitamin 
supplements containing folic acid prior to conception was associated with a reduction of 
50% to 75% of cases of spina bifida and anencephaly.11-15 More conclusively, a multi­
center randomized trial in 1991 demonstrated that folic acid protects against recurrence of
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NTD-affected pregnancies.16 A randomized controlled trial in Hungary in 1992 found 
that multivitamins containing folic acid have a protective effect on NTDs in women 
without a previously affected pregnancy.17
Based on this evidence, the United States Public Health Service (PHS) issued a 
recommendation in September 1992 that all women capable of having children consume 
400 micrograms per day (mcg/d) of folic acid to reduce the numbers of pregnancies 
affected by spina bifida and other NTDs.18 Although folic acid can be obtained through 
consumption of vitamin supplements, up to 50% of pregnancies are unplanned and the 
simplest approach to ensuring that women are protected is to routinely add folic acid to 
commonly consumed foods.
Any intervention needs to be evaluated for risks of harm. The major concern with 
adding folic acid to foods is that individuals with undiagnosed vitamin B12 deficiency 
could possibly be delayed in receiving a diagnosis. The fear is that high intakes of folic 
acid could “mask” the hematologic sign of anemia while allowing neurological damage 
to proceed untreated.2 Folic acid shares a metabolic pathway with vitamin B12, and the 
anemia associated with vitamin B12 deficiency can be resolved by increasing the intake of 
folic acid. Prolonged deficiency of vitamin B12 can result in neurological damage which, 
if left untreated, can be disabling and irreversible.
No direct evidence exists of “masking” of vitamin B12 deficiency by folic acid 
intakes.19 It is known from older studies that certain individuals with known vitamin B12 
deficiency who received folic acid alone experienced neurological damage without 
anemia. The Institute of Medicine has concluded that the lowest level of folic acid intake 
for which adverse effects have been demonstrated among individuals with vitamin B12
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deficiency is 5 milligrams per day (mg/d); due to uncertainty the safe upper level for 
consumption was set at 1 mg/d due to uncertainty.20 FDA likewise adopted a level of 1 
mg/d as the safe upper level of intake but applied this threshold to total folate intake, not 
synthetic folic acid alone.21-22
Ex ante economic evaluations of folic acid fortification
Three economic evaluations were prepared prior to the 1996 decision to require 
folic acid fortification of enriched cereal grain products. A CBA was prepared by FDA 
staff and published in the Federal Register in October 1993.3 A second CBA was 
published in 1995 by University of California researchers.4,23 Third, a CEA was 
published in 1996 by CDC researchers.5 Both the California and CDC analyses were 
presented to the FDA Folic Acid Subcommittee prior to their publication
The three ex ante economic studies all projected net economic benefits of 
fortification Table 1 summarizes the results of the three studies for the then-proposed 
fortification level of 140 mcg of folic acid per 100 grams of cereal-grain product (140 
mcg/100 g). The estimate of net monetary benefit in the two CBA studies was roughly 
$700 million in the FDA analysis and $100 million in the California analysis. The CDC 
analysis, which was a CEA, did not calculate net monetary benefit, but did estimate $5 
million in direct cost savings. The discrepancy between the FDA and California estimates 
was driven largely by differences between the willingness-to-pay (WTP) method used in 
the FDA analysis and the cost-of-illness (COI) method used in the California study. The 
FDA’s approach valued deaths averted according to the estimated average wage premium 
to compensate for risk of fatal occupational injuries, which at the time was cakulated to 
be $5 million per death averted.3 The California approach valued deaths according to lost
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productivity in future years discounted to present values using a 5% discount rate, which 
in 1991 was calculated to be $342,500 at birth.23
The three studies utilized similar estimates of the cost of fortification. The annual 
cost of fortificant was assumed to be $4 million in the FDA and CDC analyses and $3.3 
million in the California analysis. All three analyses assumed $2.5 million in analytic 
testing. The major difference was in the cost of changing food labels. In the FDA analysis 
this was a one-time cost of $20 million, which was converted to an annualized cost of 
$800,000 per year in perpetuity in the California analysis and $4.5 million in annualized 
cost in the CDC study. The California study also assumed that surveillance of adverse 
effects would be funded at a level of $5 million per year
The analyses differed with regard to the expected costs of adverse effects among 
adults with undiagnosed vitamin B12 deficiency. The FDA analysis assumed no adverse 
effects with fortification at 140 mcg/100 g Projections of costs of adverse health effects 
were much higher in the California study ($16.4 million) than in the CDC study 
($350,000). The two studies differed both for the numbers of cases of adverse effects,
500 and 89, respectively, and the average cost per case of neurological damage, $33,500 
and $3,900, respectively. The disparity in estimates reflects the lack of accurate 
information on which to make projections.
Fortification and NTD rates, ex ante and ex post
All three ex ante analyses projected modest percentage reductions in NTD rates 
that would result from fortification at 140 mcg/100 g. The range of estimates was from 
2% to 10% (Table 1). All three analyses assumed that half of NTDs could be prevented if 
women consumed 400 mcg/d of folic acid or folate and that fortification at 140 mcg/100
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g would increase average folic acid intake by 100 mcg/d, but they varied with regard to 
whether dietary folate intakes are protective and how many women would reach a 
protective level of intakes.
Following the full implementation of folic acid fortification in the United States in 
January 1998, analyses of birth defects surveillance data have estimated substantially 
larger reductions in NTD, between 20% and 30%. Data on births with spina bifida and 
anencephaly from programs without prenatal diagnosis indicate a reduction of 23% 
between 1995-96 and 1998-99, and programs that included information on prenatally 
ascertained cases recorded a 30% reduction in NTDs.24
Why the difference between the projected outcomes and the observed reductions ? 
First, rather than the projected average increase in intake of 100 mcg/d, the average 
increase in intake in the U.S. adult population may be closer to 200 mcg/d, estimated on 
the basis of observed changes in serum folate levels.25 Analysis of folate in enriched 
foods reveals that certain foods contain more than the expected amount, with enriched 
bakery products reported to contain 40% to 100% more folic acid than stated.26 Vitamin 
supplements and breakfast cereals that are voluntarily enriched with 400 mcg of folic 
acid per serving may have also contributed, although the contribution of supplements is 
believed to be quite small. Surveys conducted by the March of Dimes revealed only a 
small increase during this period in consumption of supplements containing folic acid by 
women of childbearing age, rising from 28% in 1995 to 32% in 1998 and remaining at 
that level through 2003.27-28
Second, and more importantly, the ex ante economic analyses were all very 
conservative in epidemiological modeling of the folate-NTD association owing to lack of
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information on a dose-response curve. All three analyses assumed that only women 
consuming =400 mcg/d would have a reduced risk of having a NTD-affected pregnancy. 
Data from Ireland were subsequently published that showed a dose-response relation 
between blood folate levels and NTD risk.29 Based on those data and other assumptions, a 
100 mcg/d increase in folic acid consumption would be expected to lead to a reduction in 
NTD rates in the United States of 13%25 to 22%30, while a 200 mcg/d increase would be 
associated with a 23%25 to 41%30 reduction.
The California study projected a greater percentage reduction in NTDs than the 
CDC study largely because it treated natural folate and synthetic folic acid as 
equivalently effective. The CDC study conservatively assumed that only synthetic folic 
acid would provide protection against NTDs. It has long been known that natural folate is 
limited in bioavailability compared to folic acid. The Institute of Medicine recently 
concluded that the bioavailability of folic acid is 1.7 times greater than that of dietary 
folate.20 Thus, dietary folate has some protective effect against NTDs, but substantially 
less than that of folic acid.
Canadian authorities also mandated folic acid fortification of flour and pasta in 
1998 at 150 mcg/100 g of flour and 240 mcg/100 g of pasta. The reported percentage 
reductions in NTDs (spina bifida and/or anencephaly) in provinces in the eastern half of 
Canada are 32% in Quebec,31 47% in Ontario,32 54% in Nova Scotia,33 and 78% in 
Newfoundland,34 each of which is higher than that reported in the United States. In each 
province, the post-fortification NTD rate among pregnancies was approximately 1 per 
1000, similar to the U.S. rate prior to fortification. The higher the baseline NTD rate, the 
greater the percentage decline with increased folic acid intakes. Similarly, folic acid
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supplementation in a community trial in China resulted in a 81% decline in a northern 
project area with a high baseline NTD rate and a 41% decline in a southern project area 
with a low baseline rate, with similar post-supplementation rates in both areas.35 
Ex post economic evaluation of fortification
We have performed an ex post economic evaluation of folic acid fortification. In 
line with the OMB guidance recommending that both CEA and CBA be used to evaluate 
regulatory actions affecting public health, we present estimates in both forms. First, we 
employ the same COI method used in the California ex ante CBA study. We did not 
attempt to replicate the FDA analysis, because of concerns about the applicability of the 
statistical life valuation method. Second, we present calculate the reduction in averted 
direct costs, which can be directly compared with the CDC ex ante CEA study.
We excluded NTD-affected pregnancies not ending in live birth because of the 
relatively low direct costs and difficulties with the attribution of indirect costs, as well as 
the issue of costs associated with replacement births. Birth defects surveillance data 
indicate reductions each year of approximately 612 births affected by NTDs following 
fortification, including 520 with spina bifida and 92 with anencephaly.24
Not all the reduction in NTDs can be attributed to fortification, since some 
contribution presumably has come from increases in use of vitamin supplements and of 
consumption of breakfast cereals with 400 mcg of folic acid per serving. Our base case 
analysis assumes that the observed reduction in NTD births is due entirely to fortification, 
which sets an upper bound to the benefit estimate, which is varied in a sensitivity analysis 
Our updated estimates of the costs of spina bifida are described in a book chapter 
devoted to that topic.36 The cost estimates use a 3% discount rate to adjust projected
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lifetime costs in future years to present value, which is the current standard in public 
health. In 2002 dollars, the lifetime cost associated with a birth with spina bifida is 
estimated at $636,000. Of this amount, $279,000 represents lifetime direct costs, mostly 
medical, and do not include caregiving time costs. For anencephaly, the total cost is 
$1,020,000, including $1,014,000 in indirect costs37 and $6,000 in average hospital costs 
for births with anencephaly5 updated to 2002 prices.
The actual cost of fortification is lower than was projected in the ex ante analyses. 
No evidence exists that food manufacturers are spending additional money on analytic 
testing of enriched cereal-grain products because of folic acid. Likewise, surveillance of 
adverse effects was not funded. The cost of food label changes was presumably lowered 
by the fact that manufacturers were given an 18-month window in which to change 
nutrition labels. Finally, the cost of bulk folic acid is now lower than it was in the early 
1990s; the estimated cost per ton of flour is one third lower than that estimated in the 
California study (Peter Ranum, MS, oral communication, August 7, 2004). This indicates 
an estimated annual folic acid fortificant cost of $2.2 million The sum of fortificant cost 
and an annualized cost of $800,000 for nutrition label changes yields an estimate of total 
fortification costs of $3 million per year.
We have not calculated costs associated with possible adverse health effects 
because of the absence of evidence that adverse effects have occurred. Although higher 
than projected intakes of folic acid presumably put more people at risk, the projections 
likely overstated the number of people at risk. Empirical post-fortification information is 
limited. A study conducted in one U.S. health care system found no reduction in 
diagnoses of anemia among people with vitamin B12 deficiency following fortification, as
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would have been expected if masking had occurred.38 We cannot rule out the possibility 
that some adverse effects might have occurred, although it seems likely that alert 
clinicians would have detected this if it were a widespread phenomenon
Our findings are summarized in Table 2. Following the CBA approach, the total 
economic benefit from reduction in the number of NTDs following folic acid fortification 
is estimated to be $425 million per year. Subtracting fortification cost of $3 million per 
year, the net monetary benefit is $422 million This compares with an estimate of $94 
million in the California study. We do not have data on costs associated with possible 
cases of masked anemia of vitamin B12 deficiency.
For our CEA estimates, we calculated direct cost estimates. Our preliminary 
estimate is that the averted costs of care for children born with spina bifida amount to 
$145 million per year. Subtracting $3 million for fortification yields net cost savings of 
$142 million per year, which compares with an estimate of $5 million in cost savings 
from the CDC ex ante study. The latter study also projected that there would be an annual 
gain of 898 QALYs resulting from fortification, which included projected gains from 
prevention of termination of pregnancies. Including only the QALY gains from the 
prevention of births with spina bifida or anencephaly and using the same per-person 
QALY weights as in the previous CDC study, we project that each year’s birth cohort 
gains 10,234 QALYs as a result of folic acid fortification.
These estimates imply savings in averted direct costs of more than 40 dollars for 
every dollar on average spent on fortification. This does not take into account money 
spent on research, public promotion of folic acid consumption, or evaluation through 
birth defects surveillance. Nonetheless, few public health interventions, other than
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immunizations, are found to be cost saving in terms of lower total costs of care including 
the cost of the intervention39 Folic acid fortification is unusual among public health 
interventions in the magnitude of economic benefits.
Sensitivity analyses
Our analysis is subject to two major areas of uncertainty. One is the lack of 
information on potential, undocumented cases of neurological damage secondary to 
untreated pernicious anemia. We have presented an analysis based on the best available 
data, which provides no evidence of an increase in such cases. If adverse effects had 
indeed occurred to the extent modeled in the California ex ante analysis, our estimates of 
net benefits and cost savings would be reduced by $25 million each, leaving net benefit at 
$400 million per year and cost savings at $117 million. This sensitivity analysis indicates 
that our estimates of economic benefit do not substantially depend on this factor.
A second area of uncertainty is the number of NTDs prevented that can be 
attributed to mandatory folic acid fortification. As noted, multivitamin supplement use 
increased from 28% of women of reproductive age in 1995 to 32% in 1999, a small 
increase. In the absence of information on the consumption of folic acid from foods 
voluntarily enriched at higher levels (e.g. certain breakfast cereals), we cannot calculate 
the relative contribution. For the purpose of sensitivity analysis, we assumed that 20% of 
the observed decrease in NTDs might be due to other sources of increased folic acid 
intake. On the basis of this assumption, our estimates of net benefit and net cost savings 
would be reduced to $340 million and $116 million, respectively.
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Ex post economic evaluations are underutilized in the regulatory arena. Because 
they are not required, few economic analyses are conducted after a regulation is adopted. 
Public health policy making could be enhanced by the ongoing economic evaluation of 
policies, regulatory or otherwise. Certain policies turn out to be less effective and cost- 
beneficial than expected, whereas other policies, including folic acid fortification, are 
revealed to have generated substantially more economic benefits than anticipated.
Three independent economic evaluations all concluded that folic acid fortification 
at 140 mcg/100 g would yield net economic benefits or cost savings,3-5 a conclusion 
confirmed by subsequent evidence. The FDA choice of level of fortification was not 
based on calculations of net economic benefit but on the basis of the safety standard that 
no group of people would be likely to be harmed. The FDA in 1996 cited the California 
team’s projection of 500 annual adverse effects from fortification at 140 mcg/100 g but 
chose not to take this into account in projecting the costs and benefits of fortification.
The decrease in numbers of NTDs following fortification was greater than that 
projected by the ex ante analyses. In part, this probably reflects a higher level of folic 
acid intakes than expected. The greater reduction in NTD numbers also reflects the 
conservative nature of the models used to project declines in numbers of NTDs from 
increased folic acid intakes. Economic evaluations in public health depend on 
epidemiologic data and assumptions, which play a crucial role in determining the 
magnitude of cost-benefit or cost-effectiveness.
Estimates of net benefit depend on how costs and benefits are calculated. We have 
followed the COI method of valuation of health outcomes, which is a conservative
Discussion
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approach to valuing health outcomes. Use of the WTP method could lead to a higher 
estimate of economic benefit of fortification, but validated WTP estimates for the 
prevention of lethal or disabling congenital conditions are not available. Several of the 
advantages and limitations of each health valuation approach have been reviewed.7,9
We have presented an analysis based on the best available data regarding 
outcomes following folic acid fortification. Although alert clinicians have not detected an 
unusual occurrence of neurological damage due to untreated pernicious anemia, 
conclusive evidence would require systems to monitor this outcome. Nonetheless, our 
sensitivity analysis indicates that even if adverse effects had occurred to a larger extent 
than seems likely, it would have a very small effect on our estimates of net economic 
benefit.
In conclusion, folic acid fortification has proven to be a public health success 
story in the United States and Canada. The net economic benefit and cost savings 
resulting from the prevention of these deadly and disabling birth defects far surpass 
estimates prepared prior to the implementation of fortification in the United States. For 
every dollar that has been spent on folic acid fortification in the United States, at least 40 
dollars will be saved in avoiding the costs of providing care to children with spina bifida 
who instead were born healthy as a result of their mothers’ consumption of fortified foods 
prior to conception. This does not take into account the prevention of anguish to parents 
who lose a child to death from spina bifida or anencephaly. By any measure, folic acid 
fortification provides excellent value and a remarkable return on investment. Other 
industrialized countries could benefit by following the lead of the United States and 
Canada in adopting folic acid fortification of cereal grain products.
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89 $16.1m $11m $350,000 $4.7m
Table 2. Summary of Ex Post Economic Evaluation of Folic Acid Fortification at 140 

































Both 612 $425m $422m $146m $143m
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